PROK
Prokidney Corp
NASDAQ · Biotechnology
$1.87
+0.14 (+8.09%)
Open$1.74
Previous Close$1.73
Day High$1.89
Day Low$1.74
52W High$7.13
52W Low$0.46
Volume—
Avg Volume1.11M
Market Cap562.56M
P/E Ratio—
EPS$-0.54
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+959.9% upside
Current
$1.87
$1.87
Target
$19.82
$19.82
$13.43
$19.82 avg
$25.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 240.7K | 45.98M | 42.93M |
| Net Income | -187,991,407 | 9.61M | 10.78M |
| Profit Margin | -80,507.9% | 20.9% | 25.1% |
| EBITDA | -547,638,914 | 17.18M | 13.92M |
| Free Cash Flow | — | 13.69M | 9.06M |
| Rev Growth | — | +20.4% | +3.7% |
| Debt/Equity | 0.00 | 0.62 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |